• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Processa Pharmaceuticals, Inc. (Amendment)

    8/10/21 5:02:22 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PCSA alert in real time by email
    SC 13G/A 1 d8919322_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Processa Pharmaceuticals, Inc.
    (Name of Issuer)

     

     

    Common Stock, $0.0001 par value per share
    (Title of Class of Securities)

     

     

    74275C205
    (CUSIP Number)

     

     

    August 4, 2021
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *       The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     


    CUSIP No
    74275C205    

     

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      Manchester Explorer, L.P.
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      142,427  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      142,427  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      142,427  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)  
      EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0.9%  
         

    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      PN  
     
     

     

     


    CUSIP No.
    74275C205    

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Manchester Management Company, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      142,427  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      142,427  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      142,427  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)  
      EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0.9%  
         


    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      OO  

     

     
     

     

     


    CUSIP No.
    74275C205    

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Manchester Management PR, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Puerto Rico  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      142,427  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      142,427  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      142,427  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)  
      EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0.9%  
         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    OO

     
         
     
     

     

     


    CUSIP No.
    74275C205    

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      JEB Partners, L.P.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      0  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      0  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      0  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)  
      EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0%  
         

    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      OO  

     

     
     

     

     


    CUSIP No.
    74275C205    

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      James E. Besser  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      142,427  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      142,427  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      142,427  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)  
      EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0.9%  
         

    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IN  

     

     
     

     

     


    CUSIP No.
    74275C205    

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Morgan C. Frank  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      142,427  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      142,427  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      142,427  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)  
      EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0.9%  
         

    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IN  

     

     
     

     

     

     

    CUSIP No. 74275C205    

     

           
    Item 1. (a). Name of Issuer:  
           
        Processa Pharmaceuticals, Inc.  
           
      (b). Address of issuer's principal executive offices:  
           
       

    7380 Coca Cola Drive, Suite 106

    Hanover, MD 21076

     
           
    Item 2. (a). Names of persons filing:  
           
       

    Manchester Explorer, L.P.

    Manchester Management Company, LLC

    Manchester Management PR, LLC

    JEB Partners, L.P.

    James E. Besser

    Morgan C. Frank

     

     

     

     

     

      (b). Address or principal business office or, if none, residence:  
           
       

    Manchester Explorer, L.P.

    c/o Manchester Management Company, LLC

    2 Calle Candina, #1701

    San Juan, Puerto Rico, 00907

    United States of America

     

    Manchester Management Company, LLC

    2 Calle Candina, #1701

    San Juan, Puerto Rico, 00907

    United States of America

     

    Manchester Management PR, LLC

    2 Calle Candina, #1701

    San Juan, Puerto Rico, 00907

    United States of America

     

    JEB Partners, L.P.

    2 Calle Candina, #1701

    San Juan, Puerto Rico, 00907

    United States of America

     

    James E. Besser

    c/o Manchester Management Company, LLC

    2 Calle Candina, #1701

    San Juan, Puerto Rico, 00907

    United States of America

     

    Morgan C. Frank

    c/o Manchester Management Company, LLC

    2 Calle Candina, #1701

    San Juan, Puerto Rico, 00907

    United States of America

     

     
           
      (c). Citizenship:  
           
       

    Manchester Explorer, L.P. – Delaware limited partnership

    Manchester Management Company, LLC – Delaware limited liability company

    Manchester Management PR, LLC - Puerto Rico limited liability company

    JEB Partners, L.P. – Delaware limited partnership

    James E. Besser – United States of America

    Morgan C. Frank – United States of America

     

     
           
      (d). Title of class of securities:  
           
        Common Stock, $0.0001 par value per share  
           
      (e). CUSIP No.:  
           
        74275C205  

     

     
     

     

    Item 3. If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
           
      (a) [_]

    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

      (b) [_]

    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

      (c) [_]

    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

      (d) [_]

    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

      (e) [_]

    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f) [_]

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) [_]

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) [_]

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) [_]

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) [_]

    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

      (k) [_] Group, in accordance with §240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:
           
       
    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
             

     

         
      (a) Amount beneficially owned:
         
       

    Manchester Explorer, L.P. – 142,427

    Manchester Management Company, LLC - 142,427

    Manchester Management PR, LLC – 142,427

    JEB Partners, L.P. – 0

    James E. Besser – 142,427

    Morgan C. Frank – 142,427

         
      (b) Percent of class:
         
       

    Manchester Explorer, L.P. – 0.9%

    Manchester Management Company, LLC – 0.9%

    Manchester Management PR, LLC – 0.9%

    JEB Partners, L.P. – 0%

    James E. Besser – 0.9%

    Morgan C. Frank – 0.9%

         
     
     

     

      (c) Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote  
             
          Manchester Explorer, L.P. - 0
          Manchester Management Company, LLC – 0
          Manchester Management PR, LLC - 0
          JEB Partners, L.P. – 0
          James E. Besser – 0  
          Morgan C. Frank – 0  
       

     

    (ii)

     

    Shared power to vote or to direct the vote

     
             
          Manchester Explorer, L.P. – 142,427
          Manchester Management Company, LLC – 142,427
          Manchester Management PR, LLC – 142,427
          JEB Partners, L.P. – 0
          James E. Besser – 142,427  
          Morgan C. Frank –142,427  

     

        (iii) Sole power to dispose or to direct the disposition of  
             
          Manchester Explorer, L.P. – 0
          Manchester Management Company, LLC – 0
          Manchester Management PR, LLC - 0
          JEB Partners, L.P. – 0
          James E. Besser – 0  
          Morgan C. Frank – 0  
       

     

    (iv)

     

    Shared power to dispose or to direct the disposition of

     
             
          Manchester Explorer, L.P. – 142,427
          Manchester Management Company, LLC – 142,427
          Manchester Management PR, LLC – 142,427
          JEB Partners, L.P. – 0
          James E. Besser – 142,427  
          Morgan C. Frank – 142,427  

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  [X].
     

     

     

       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     

     

    N/A

     
     

     

       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     
     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      August 10, 2021
      (Date)
       
      MANCHESTER EXPLORER, L.P.*
       
      /s/ James E. Besser
      (Signature)
       
      James E. Besser, Managing Member of the General Partner
      (Name/Title)
       
      Manchester Management Company, LLC*
       
      /s/ James E. Besser
      (Signature)
       
      James E. Besser, Managing Member
      (Name/Title)
       
      Manchester Management PR, LLC*
       
      /s/ James E. Besser
      (Signature)
       
      James E. Besser, Managing Member
      (Name/Title)
       
       
      JAMES E. BESSER
       
      /s/ James E. Besser
      (Signature)
       
      MORGAN C. FRANK
       
      /s/ Morgan C. Frank
      (Signature)

     

     

     

     

    * The Reporting Person disclaims beneficial ownership in the common stock reported herein except to the extent of his pecuniary interest therein.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     
     

     

     

    Exhibit A

     

     

    AGREEMENT

     

     

    The undersigned agree that this amendment number one to Schedule 13G, dated August 10, 2021, relating to the Common Stock, $0.0001 par value per share, of Processa Pharmaceuticals, Inc. shall be filed on behalf of the undersigned.

     

      August 10, 2021
      (Date)
       
      MANCHESTER EXPLORER, L.P.
       
      /s/ James E. Besser
      (Signature)
       
      James E. Besser, Managing Member of the General Partner
      (Name/Title)
       
      Manchester Management Company, LLC
       
      /s/ James E. Besser
      (Signature)
       
      James E. Besser, Managing Member
      (Name/Title)
       
      Manchester Management PR, LLC
       
      /s/ James E. Besser
      (Signature)
       
      James E. Besser, Managing Member
      (Name/Title)
       
       
      JAMES E. BESSER
       
      /s/ James E. Besser
      (Signature)
       
      MORGAN C. FRANK
       
      /s/ Morgan C. Frank
      (Signature)

     

     

     

     

     

     

     

    Get the next $PCSA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PCSA

    DatePrice TargetRatingAnalyst
    4/25/2024$8.00Buy
    H.C. Wainwright
    8/3/2021$20.00Outperform
    Oppenheimer
    8/2/2021$20.00Outperform
    Oppenheimer
    More analyst ratings

    $PCSA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

      HANOVER, Md., April 15, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced that Dr. David Young, Founder and President of Research & Development, has been invited to present at the World Orphan Drug Congress USA 2025. Dr. Young's presentation, titled "Applying Principles of FDA's Project Optimus to Oncology and Non-Oncology Rare Diseases," will take place on Tuesday, April 24, 2025, at 2:00 p.m. Eastern Time at the Boston Convention & Exhibition Center. Dr. Young's presentation will explore how

      4/15/25 8:00:00 AM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

      HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the MedInvest Biotech and Pharma Investor Conference being held March 27-28, 2025, at Cooley's law office in New York City. Management will present a corporate overview on Friday, March 28th at 9:40 a.m. Eastern time, and will hold one-on-one meetings with registered investors and other attendees throughout the conference. The presentation will be available on Processa's website. For more information

      3/18/25 8:30:00 AM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

      HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the 2025 BIO CEO & Investor Conference being held February 10-11, 2025, at the New York Marriott Marquis. Management will present a corporate overview on Tuesday, February 11 at 10:00 a.m. Eastern time in the Plymouth Room, and will hold one-on-one meetings with registered investors and other attendees throughout the conference. Those interested in scheduling a meeting with Processa management are encou

      2/7/25 8:00:00 AM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Processa Pharmaceuticals, Inc. (Amendment)

      SC 13G/A - Processa Pharmaceuticals, Inc. (0001533743) (Subject)

      8/10/21 5:02:22 PM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Processa Pharmaceuticals, Inc.

      SC 13G - Processa Pharmaceuticals, Inc. (0001533743) (Subject)

      6/11/21 1:11:49 PM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Processa Pharmaceuticals, Inc. (Amendment)

      SC 13G/A - Processa Pharmaceuticals, Inc. (0001533743) (Subject)

      4/8/21 5:15:23 PM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCSA
    Financials

    Live finance-specific insights

    See more
    • Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results

      First patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from preclinical studies support NGC-Iri's ability to deliver more SN-38 to tumors compared with either irinotecan or Onivyde® HANOVER, Md., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, provides updates on its product pipeline, upcoming milestones and business activities, and reports financial results for the three and nine months ended September 30, 2024. "We continued to make progres

      10/30/24 4:15:00 PM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Processa Pharmaceuticals Provides Product Pipeline and Financial Update

      Phase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity Preclinical studies demonstrated NGC-Iri delivers more cancer-killing SN-38 molecules to tumor than either irinotecan or Onivyde® HANOVER, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, provides updates on its product pipeline, upcoming milestones and business activities, and reports financial results for the three and six mont

      8/28/24 8:00:00 AM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

      HANOVER, MD, March 23, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a developer of Next Generation Chemotherapy drugs that provide a better safety-efficacy profile than their widely used FDA-approved counterparts, today announced that it will host a conference call and live webcast on March 30, 2023 at 4:30 p.m. EST to discuss its 2022 results and provide an update on its clinical pipeline for 2023. Conference Call Information To participate in this event, please log-on or dial-in approximately 5 to 10 minutes before the beginning of the call. Date: March 30, 2023Time: 4:30 p.m. ETToll Free: 888-506-0062Internatio

      3/23/23 8:30:00 AM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business - Strategy Off Lin Patrick converted options into 14,482 shares and covered exercise/tax liability with 4,814 shares, increasing direct ownership by 33% to 38,727 units (SEC Form 4)

      4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

      4/11/25 5:22:45 PM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Bigora Sian converted options into 15,059 shares and covered exercise/tax liability with 3,311 shares, increasing direct ownership by 54% to 33,626 units (SEC Form 4)

      4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

      4/11/25 5:17:49 PM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Administrative Officer Guy Wendy converted options into 14,482 shares, increasing direct ownership by 122% to 26,339 units (SEC Form 4)

      4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

      4/11/25 5:20:21 PM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCSA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Yorke Justin W bought $9,889 worth of shares (12,400 units at $0.80) (SEC Form 4)

      4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

      1/31/25 5:06:27 PM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Ng George K bought $69,542 worth of shares (87,200 units at $0.80) (SEC Form 4)

      4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

      1/29/25 5:05:00 PM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pres. Research & Development Young David bought $99,289 worth of shares (124,500 units at $0.80), increasing direct ownership by 154% to 205,405 units (SEC Form 4)

      4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

      1/29/25 4:24:39 PM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCSA
    Leadership Updates

    Live Leadership Updates

    See more
    • Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer

      HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the appointment of Russell L. Skibsted as Chief Financial Officer (CFO), effective immediately. Mr. Skibsted succeeds James Stanker, who is retiring and staying on in an advisory role to assist in the transition. "We are delighted to welcome Russell to Processa's executive team. His proven record in finance and capital markets combined with a deep understanding of the complexities inherent in the life sciences make him a

      7/17/24 8:00:00 AM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

      FDA and Processa agree to expand NGC-Cap development into breast cancer providing a more efficient path to approval FDA agrees that existing data and studies can be used to support the Phase 2 breast cancer trial design HANOVER, MD, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces it plans to expand the development of Next Generation Capecitabine ("NGC-Cap") into the treatment of advanced or metastatic breast cancer beginning with its ne

      1/19/24 7:45:00 AM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

      HANOVER, MD, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focusing on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces today that industry veteran George Ng has been appointed to serve as the Company's Chief Executive Officer and as a Board Director as of August 8, 2023. Dr. David Young will focus his efforts on the development of the Next Generation Chemotherapy (NGC) drugs as President of Research and Development and as a board member. "We are thrilled to have George assume the leadership of ou

      8/8/23 8:15:00 AM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on AirGate PCS with a new price target

      H.C. Wainwright initiated coverage of AirGate PCS with a rating of Buy and set a new price target of $8.00

      4/25/24 6:22:04 AM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Processa Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Processa Pharmaceuticals with a rating of Outperform and set a new price target of $20.00

      8/3/21 4:49:09 AM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Processa Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Processa Pharmaceuticals with a rating of Outperform and set a new price target of $20.00

      8/2/21 4:20:20 PM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCSA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Processa Pharmaceuticals Inc.

      10-Q - Processa Pharmaceuticals, Inc. (0001533743) (Filer)

      5/8/25 4:06:35 PM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Processa Pharmaceuticals Inc.

      PRE 14A - Processa Pharmaceuticals, Inc. (0001533743) (Filer)

      5/1/25 4:05:36 PM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Processa Pharmaceuticals Inc.

      10-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)

      3/20/25 4:31:24 PM ET
      $PCSA
      Biotechnology: Pharmaceutical Preparations
      Health Care